AMIX (Autonomix Medical) Intrinsic Value: Projected FCF: $0.00 (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMIX Autonomix Medical Inc AMIX
15 GF Score
Price $11.93
! 2 Warning Signs
View Full Analysis

What is Autonomix Medical Intrinsic Value: Projected FCF?

Autonomix Medical AMIX -1.40% 15 Intrinsic Value: Projected FCF is $0.00 as of Aug. 06, 2026. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 394 Medical Devices & Instruments companies, Autonomix Medical ranks worse than 253806.85% on this metric.

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2026-08-06), Autonomix Medical's Intrinsic Value: Projected FCF is $0.00. The stock price of Autonomix Medical is $11.93. Therefore, Autonomix Medical's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Autonomix Medical's Intrinsic Value: Projected FCF or its related term are showing as below:

AMIX's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.475
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Autonomix Medical  (NAS:AMIX) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Autonomix Medical's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=11.93/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Autonomix Medical Intrinsic Value: Projected FCF Related Terms


Autonomix Medical Intrinsic Value: Projected FCF Historical Data

* Premium members only.

The historical data trend for Autonomix Medical's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autonomix Medical Intrinsic Value: Projected FCF Chart

Autonomix Medical Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Intrinsic Value: Projected FCF
0.00 0.00 0.00 0.00

Autonomix Medical Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AMIX vs AEMD, NUMD, ESMC: Intrinsic Value: Projected FCF Comparison

For the Medical Devices subindustry, Autonomix Medical's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Autonomix Medical Price-to-Projected-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Autonomix Medical's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Autonomix Medical's Price-to-Projected-FCF falls into.


AMIX
15GF Score
Autonomix Medical Inc AMIX
Intrinsic Value: Projected FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Autonomix Medical Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


What does a Intrinsic Value: Projected FCF of $0.00 mean?
Autonomix Medical (AMIX) has a Intrinsic Value: Projected FCF of $0.00 as of Aug. 06, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Autonomix Medical and its competitors. According to the industry distribution chart, Autonomix Medical ranks #999999 out of 394 companies in the Medical Devices & Instruments industry.
Is Autonomix Medical's Intrinsic Value: Projected FCF too high?
Autonomix Medical's current Intrinsic Value: Projected FCF is $0.00. Based on the distribution chart, Autonomix Medical ranks #999999 out of 394 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's Intrinsic Value: Projected FCF compare to AEMD and NUMD?
According to the Medical Devices & Instruments industry distribution chart, Autonomix Medical ranks #999999 out of 394 companies for Intrinsic Value: Projected FCF. This places Autonomix Medical in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.48, based on 394 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Autonomix Medical and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autonomix Medical's current Intrinsic Value: Projected FCF is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current Intrinsic Value: Projected FCF of $0.00. The current Intrinsic Value: Projected FCF is $0.00. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current Intrinsic Value: Projected FCF is $0.00 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Autonomix Medical Business Description

Address 21 Waterway Avenue, Suite 300, Woodlands, TX, USA, 77380
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score

Get the complete analysis for AMIX

Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.93
Price